CLINICAL_TRIALS
withdrawal
· 2024-12-02
Clinical Trial Update: A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) [Phase 3]
Summary
A Phase 3 trial of Valneva's chikungunya vaccine VLA1553 (NCT06028841) has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Valneva Austria GmbH | Conditions: Chikungunya Virus Infection | Phase 3 | Status: WITHDRAWN